Back to search results

Improving Medication Management for World Trade Center Responders

This study aims to help World Trade Center (WTC) responders, aged 50 and older, who are taking many medications (polypharmacy). As WTC responders get older, they may be taking five or more medications, which can lead to side effects. This research will test if an educational brochure can help you and your doctor discuss reducing or stopping medications that may no longer be needed or could cause harm. The brochure focuses on specific medication classes like proton pump inhibitors (PPIs), benzodiazepines (BZs), and others. Success will be measured by changes in your Brief Medication Questionnaire 2 (BMQ2) score after 6 months. This study is currently unclear on its recruitment status and plans to enroll 50 participants.

Study design
This is an interventional study planning to enroll 50 participants. It is not specified if it is randomized or blinded.
What's involved
You will receive an educational brochure about one of five medication classes. The study will measure your Brief Medication Questionnaire 2 (BMQ2) score at 6 months after you join.
Compensation
Not stated in the trial record.
Follow-up
Your medication management will be assessed at 6 months after you join the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07022990

Improving Medication Management in World Trade Center Responders

Recruiting
NAAges 50+InterventionalHealth services
Icahn School of Medicine at Mount Sinai
~50 participants
Updated 2025-06-15 on ClinicalTrials.gov
What's tested:Educational brochure for deprescribing

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Brief Medication Questionnaire 2 (BMQ2)
Measured over 6 months after study enrollment

Conditions

Polypharmacy

Explore related trials

Polypharmacy

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Fred Ko, MD · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai

Who to contact

Patricia Kim
[email protected]
212-241-9370
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

A WTC responder already enrolled in the "Promoting Healthy Aging Among WTC Responders: Frailty Trajectories and Intervention Strategies" study cohort
aged 50 years or older, and
taking one of the five medication classes:
proton pump inhibitors (PPIs),
benzodiazepine (BZs) and
non-benzodiazepine sedative hypnotics ("Z-drugs"),
first-generation antihistamines (FGA), and
skeletal muscle relaxants (SMR).

Exclusion

None

What this trial measures

  • Brief Medication Questionnaire 2 (BMQ2)6 months after study enrollment

    Brief Medication Questionnaire 2 (BMQ2) to measure participants feel/views about Z Drugs, Skeletal Muscle Relaxants, Proton Pump Inhibitors and Benzodiazepines. Min scale: Strongly Agree - Max scale: Strongly Disagree. Higher score means patient strongly disagrees with the extent medications makes them feel/views about their medication.